June 3, 2020 / 12:14 PM / a month ago

BRIEF-Chemocentryx Trial Of Avacopan In ANCA-Associated Vasculitis Highlighted In Presentations At EULAR

June 3 (Reuters) - ChemoCentryx Inc:

* CHEMOCENTRYX PHASE III ADVOCATE TRIAL OF AVACOPAN IN ANCA-ASSOCIATED VASCULITIS HIGHLIGHTED IN ORAL PLENARY PRESENTATIONS AT EULAR AND ERA-EDTA CONGRESSES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below